28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Breast Cancer”
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Breast Cancer” shown below:
1. “Applying Deep Learning for Breast Cancer Detection in Radiology”
by Ella Mahoro and Moulay A. Akhloufi
Curr. Oncol. 2022, 29(11), 8767–8793; https://doi.org/10.3390/curroncol29110690
Available online: https://www.mdpi.com/1718-7729/29/11/690
2. “Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?”
by Liqin Yao, Gang Jia, Lingeng Lu and Wenxue Ma
Curr. Oncol. 2022, 29(7), 4902–4913; https://doi.org/10.3390/curroncol29070389
Available online: https://www.mdpi.com/1718-7729/29/7/389
3. “Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?”
by Susan G. R. McDuff and Rachel C. Blitzblau
Curr. Oncol. 2023, 30(1), 392–400; https://doi.org/10.3390/curroncol30010032
Available online: https://www.mdpi.com/1718-7729/30/1/32
4. “Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program”
by Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini et al.
Curr. Oncol. 2022, 29(9), 6635–6641; https://doi.org/10.3390/curroncol29090521
Available online: https://www.mdpi.com/1718-7729/29/9/521
5. “Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?”
by Sarah Strickland and Gulisa Turashvili
Curr. Oncol. 2022, 29(8), 5664–5681; https://doi.org/10.3390/curroncol29080447
Available online: https://www.mdpi.com/1718-7729/29/8/447
6. “Efficacy and Accuracy of Using Magnetic Seed for Preoperative Non-Palpable Breast Lesions Localization: Our Experience with Magseed”
by Anna D’Angelo, Charlotte Marguerite Lucille Trombadori, Flavia Caprini, Stefano Lo Cicero, Valentina Longo, Francesca Ferrara, Simone Palma, Marco Conti, Antonio Franco, Lorenzo Scardina et al.
Curr. Oncol. 2022, 29(11), 8468–8474; https://doi.org/10.3390/curroncol29110667
Available online: https://www.mdpi.com/1718-7729/29/11/667
7. “Prevalence and Persistence of Anxiety and Depression over Five Years since Breast Cancer Diagnosis—The NEON-BC Prospective Study”
by Catarina Lopes, Luisa Lopes-Conceição, Filipa Fontes, Augusto Ferreira, Susana Pereira, Nuno Lunet and Natália Araújo
Curr. Oncol. 2022, 29(3), 2141–2153; https://doi.org/10.3390/curroncol29030173
Available online: https://www.mdpi.com/1718-7729/29/3/173
8. “Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?”
by Angel Montero and Raquel Ciérvide
Curr. Oncol. 2022, 29(12), 9767–9787; https://doi.org/10.3390/curroncol29120768
Available online: https://www.mdpi.com/1718-7729/29/12/768